⌕
Roivant Sciences · ROIV · Nasdaq
Tenet 42 · Weak
Compare
$39.53−1.15%At closeTenet 42 · Weak
$39.53−0.46 (−1.15%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD
$39.36−0.17 (−0.43%)
Pre-market: Nov 16, 2026, 8:01 AM ET· last 1-minute bar

Roivant Sciences (ROIV) Stock

Roivant Sciences (ROIV) closed at $39.53 on Nov 13, 2026; its Tenet Score is 42 of 100 against 297 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

26 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$39.53
Nov 13, 2026
Market cap
$28.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
19.96 – 42.50
low → high · as of close, Nov 13, 2026
Tenet Score
42/100
Weak · 297 Healthcare peers

Industry: Drugs

Roivant Sciences Ltd scores 42/100. Weak. Strongest on financial health, growth is the soft spot versus 297 Healthcare peers.

Tenet Score · vs sector

n=297
42/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
29
Quality
44
Health
91
Growth
6

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityDHealthAGrowthFMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
7.1×
price to book value
P/S
697.2×
price to fiscal 2025 sales
ROE
−8%
return on equity
Operating margin
—
no operating margin on file
Net margin
−939.0%
of revenue kept
Current ratio
15.56
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Roivant Sciences Ltd

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophospha…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=297) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 165 US ETFs · top wrappers by weightSee all ETFs holding ROIV →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
BeOne Medicines LtdONC64$47.6B
Biogen IncBIIB39$37.5B
Revolution Medicines IncRVMD39$37.3B
Zoetis IncZTS59$34.1B
Illumina IncILMN51$31.3B
Insmed IncINSM33$26.6B
United Therapeutics CorpUTHR72$25.2B
Incyte Corp.INCY60$24.7B
Alnylam Pharmaceuticals IncALNY51$22.1B
Medpace Holdings IncMEDP59$18.3B

Compare Roivant Sciences with

What sector and industry is Roivant Sciences in?

Roivant Sciences is in the Healthcare sector and the Drugs industry.

What is Roivant Sciences' Tenet Score?

Roivant Sciences' Tenet Score is 42 out of 100, ranked against 297 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.